Affymetrix on the Ascent
In all sectors of the market, the winners are sometimes lost amid the combined performance of their brethren, losers included, and that's certainly the case for the components of the Amex Biotech Index.
Looking at the changes in those 17 stocks during the past 52 weeks reveals one clear winner, and by a sizable margin: Affymetrix (AFFX), a maker of chips used to analyze the effects of drugs on genes. As of June 17, its shares are up 68% in the past year.
What investors are trying to determine is whether Affymetrix's performance is the start of a long-term trend or something that can be erased as quickly as it developed. Views are mixed, but looking at how the company got to be the best performer of the last 12 months could provide some clues as to what the future will bring.
In the short term, Affymetrix stands to benefit from interest in the in-depth testing of drug toxicity that has emerged in the aftermath of Merck's (MRK) withdrawal of Vioxx and Biogen Idec's (BIIB) suspension of Tysabri sales.Affymetrix, based in Santa Clara, Calif., makes products that help researchers observe the effects of drugs on patients by monitoring changes in gene expressions. The company expects to launch several DNA-analysis products, as well as automated target preparation hardware developed jointly with Caliper Life Sciences (CALP), in the not-too-distant future. While these new products are expected to be well-received by academics and Big Pharma, the long-term effects of a shift in the standards of pharmaceutical development may have even greater implications for the company and for its sector.
Achieving TargetsEven after the run-up in the past year, Paul R. Knight of Thomas Weisel Partners still sees room for additional gains in Affymetrix stock. In the near term, the stock's performance will be driven by demand for tests to screen out compounds that are likely to fail later in development because of toxicity or lack of effectiveness. Longer term, the benefits could come as tests are used to analyze an individual's genetic makeup and the responses caused by drugs, Knight says.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV